Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 15, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
5928
Shown on this page
12
Current sort
Recently updated
Condition scope
Lung Cancer
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings
NSCLC small cell lung cancer EGFR ALK KRAS

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Lung Cancer. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1069–1080 of 5,928 matching trials for Lung Cancer.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 2 Interventional Results available

Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

NCT03662074
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Gemcitabine, Nivolumab
Drug · Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Completed Not applicable Interventional Results available

Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer

NCT03337399
View directory record Official record
Conditions
Lung Cancer
Interventions
Stepped PC, Early Integrated PC
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

NCT02905591
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions
Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Completed Phase 1Phase 2 Interventional

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

NCT06532032
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Docetaxel
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Irvine, California • Los Alamitos, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

NCT02535312
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions
Cisplatin, Methoxyamine, Pemetrexed Disodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

NCT04093167
View directory record Official record
Conditions
Lung Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Active, not recruiting Not applicable Interventional

Adaptive Symptom Self-Management Immunotherapy Study

NCT05715255
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Lung Cancer, Skin Cancer, Rectum Cancer
Interventions
Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C), Active control comparator
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Tucson, Arizona • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Recruiting Phase 1Phase 2 Interventional

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

NCT05039632
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Solid Neoplasm
Interventions
Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Recruiting Phase 1 Interventional

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

NCT07094113
View directory record Official record
Conditions
KRAS Altered Advanced or Metastatic Solid Tumors
Interventions
AMG 410, Pembrolizumab, Panitumumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

NCT04606771
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib + Savolitinib, Savolitinib + Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Duarte, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

NCT02718066
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
Interventions
HBI-8000 in combination with nivolumab
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • Port Saint Lucie, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 15, 2026, 2:28 AM EST
Recruiting No phase listed Observational

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

NCT06410300
View directory record Official record
Conditions
Lung Cancer
Interventions
Curative Radiotherapy, Immunotherapy
Radiation · Drug
Lead sponsor
Bo Lu
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Columbia, Missouri • New Brunswick, New Jersey • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 15, 2026, 2:28 AM EST

About this Lung Cancer clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Lung Cancer.